Blue Fin Capital Inc. Sells 492 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Blue Fin Capital Inc. lessened its position in shares of iShares Biotechnology ETF (NASDAQ:IBBGet Rating) by 4.1% in the 3rd quarter, HoldingsChannel reports. The fund owned 11,568 shares of the financial services provider’s stock after selling 492 shares during the period. Blue Fin Capital Inc.’s holdings in iShares Biotechnology ETF were worth $1,352,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Hoey Investments Inc. bought a new position in shares of iShares Biotechnology ETF during the 2nd quarter worth approximately $25,000. Close Asset Management Ltd bought a new position in shares of iShares Biotechnology ETF during the 2nd quarter worth approximately $27,000. Running Point Capital Advisors LLC bought a new position in shares of iShares Biotechnology ETF during the 2nd quarter worth approximately $51,000. Capital Investment Advisory Services LLC raised its stake in shares of iShares Biotechnology ETF by 1,954.5% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 452 shares of the financial services provider’s stock worth $53,000 after acquiring an additional 430 shares in the last quarter. Finally, Castle Wealth Management LLC bought a new position in shares of iShares Biotechnology ETF during the 2nd quarter worth approximately $55,000. Institutional investors own 58.02% of the company’s stock.

iShares Biotechnology ETF Trading Up 1.1 %

NASDAQ IBB opened at $135.47 on Monday. iShares Biotechnology ETF has a 52 week low of $104.29 and a 52 week high of $138.74. The company has a 50 day moving average price of $133.62 and a 200 day moving average price of $127.57.

iShares Biotechnology ETF Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 19th. Shareholders of record on Wednesday, December 14th were given a dividend of $0.101 per share. This represents a $0.40 annualized dividend and a yield of 0.30%. The ex-dividend date of this dividend was Tuesday, December 13th. This is an increase from iShares Biotechnology ETF’s previous quarterly dividend of $0.03.

iShares Biotechnology ETF Profile

(Get Rating)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Further Reading

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBGet Rating).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.